Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab + nab-paclitaxel is a combination regimen of two drugs: toripalimab, a recombinant humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), and nab-paclitaxel, an albumin-bound formulation of the microtubule inhibitor paclitaxel. The combination is under investigation as a first-line therapy for metastatic or recurrent triple-negative breast cancer (TNBC), particularly in patients with tumors expressing PD-L1, and has recently demonstrated significant improvement in progression-free survival and a tolerable safety profile in the phase 3 TORCHLIGHT trial. Toripalimab enhances antitumor immune responses by blocking PD-1, thus restoring T cell activity, while nab-paclitaxel disrupts microtubule function during cell division and enhances immune responses by modulating the tumor microenvironment[1][2][3][4][5].
- Brand names
- TuoyiKeailiAbraxane
- Other names
- toripalimab plus nab-paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on toripalimab + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + nab-paclitaxel.